 Life Science Investor Mandates (Mar. 19 - Mar. 25) |
| |
|
Seeking Preclinical Biologic Opportunities
|
Seeking Therapeutics, Devices and Diagnostics Across the United States
|
|
Seeking Broad Range of Medical Devices Throughout the US and EU
|
|
Looking for Early Stage Therapeutics, Devices and Tools
|
|
Six Takeaways from Women In Bio Shark Tank
|
Four Reasons Why It Is Never Too Early to Build Relationships with Investors
|
RESI @ TMCx Cardiology Investors Panel Announcement
|
|
RESI Conference Group's Upcoming Events
|
| |
|
|
|
|
By Lucy Parkinson, Senior Research Manager, LSN
Last night in Cambridge, LSN joined Women In Bio for a Shark Tank-style pitch event. The audience heard pitches from five life science entrepreneurs. Across the table from them were four experienced early stage life science investors playing the role of "sharks".
So what did we learn from these life science innovators and from the sharks' cutting responses to their pitches?
1. Where women's health meets personalized healthcare, there are significant unmet needs that startups can target.
Personalized medicine was a significant theme of the event, and three of our innovators are targeting major problems in the current standard of care for women's cancers. By using biomarker diagnostics, personalized monitoring devices, and nanotech drug delivery mechanisms, these entrepreneurs hope to offer earlier detection, personalized treatment options, and targeted treatment to women with ovarian and breast cancer...
|
 |
 |
|
 Entrepreneurs we work with often ask us when they should start contacting investment firms. Almost invariably, our answer is as soon as possible. That doesn't mean a company should feel rushed into sending out unfinished, sloppy, or overly cumbersome marketing materials. You should take the time to organize your brand, from logo to tagline to pitch deck and executive summary, so that you have a professional and concise package. Any upcoming data or potential partnerships or collaborations can be easily added into the materials as they come into fruition.
If a company is waiting for an event or to receive certain data before formally fundraising, outreach can be framed as an introduction to the company, rather than a direct solicitation for funds. In this case the purpose is simply to begin a relationship. As always when reaching out to investors, it is crucial that you contact people who have interest in your sector and technology, otherwise they are unlikely to be willing to engage in even an introductory conversation or be able to help you when you are formally seeking capital. Building investor relationships early allows companies to...
|
|
 |
|
By Nono Hu, Senior Manager, Branding & Messaging, LSN
The cardiovascular sector presents unique challenges both to entrepreneurs and investors. The steep cost of Phase III trials and the strict regulatory standards applied to cardio drugs make investing in cardiovascular products a risky endeavour. Investors who dare to take on this field are rewarded with access to large markets, including a growing need for new cardio solutions in emerging economies. In addition to investors who take on cardio for the potential ROI, nonprofit funders see the potential for their dollars to make a significant global impact by backing early-stage companies.
For RESI @ TMCx, LSN has assembled a panel of veteran investors who are focused on meeting these challenges, Moderated by William Kohlbrenner, Consulting Scientist, Boston Innovation Capital & Scientist-in-Residence, Life Science Nation the audience will hear from:
|
|
  |
|
|
